Amy Mehta
Ophthalmology · New York, NYNPI 1942610977
Payments from drug & device makers
Across 280 payments — averaging $96.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$21K
- Alcon$1K
- NEW World Medical,inc.$927
- Glaukos Corporation$477
- Aerie Pharmaceuticals, Inc.$404
- Oyster Point Pharma, Inc.$386
- plus $3K from 26 others
What the payments were for
- Consulting fees$2,3009%
- Speaking & faculty fees$13,80051%
- Travel & lodging$1,1004%
- Food & beverage$9,80336%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 115 | $20,819 |
| Alcon | 41 | $1,422 |
| NEW World Medical,inc. | 8 | $927 |
| Glaukos Corporation | 6 | $477 |
| Aerie Pharmaceuticals, Inc. | 4 | $404 |
| Oyster Point Pharma, Inc. | 20 | $386 |
| Ivantis, Inc | 2 | $228 |
| Bausch & Lomb Americas Inc. | 11 | $218 |
| Biotissue Holdings Inc. | 7 | $199 |
| Harrow Eye, LLC | 9 | $193 |
| Ocular Therapeutix, Inc. | 5 | $188 |
| Mallinckrodt Hospital Products Inc. | 2 | $164 |
| Rxsight Inc | 3 | $157 |
| Carl Zeiss Meditec USA, Inc. | 1 | $134 |
| Tarsus Pharmaceuticals, Inc. | 6 | $122 |
| Kala Pharmaceuticals, Inc. | 1 | $122 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $118 |
| GSK | 7 | $117 |
| Sight Sciences, Inc. | 5 | $85 |
| Haag-streit USA, Inc. | 1 | $73 |
| Sun Pharmaceutical Industries Inc. | 3 | $64 |
| Dompe US, Inc. | 2 | $62 |
| Thea Pharma Inc. | 3 | $61 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $52 |
| Rayner Intraocular Lenses Limited | 2 | $44 |
| Beaver-visitec International, Inc. | 2 | $41 |
| Alimera Sciences, Inc. | 2 | $38 |
| Eyevance Pharmaceuticals LLC | 2 | $36 |
| Amgen | 1 | $29 |
| Novartis | 1 | $28 |
| AstraZeneca | 1 | $21 |
| Merck | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$18,244
- Ahmed Glaucoma Valve$619
- Kahook Dual Blade$619
- Streamline Surgical System$409
- Rhopressa$392
- Rocklatan$392
- iDoseTR$294
- XEN GLAUCOMA TREATMENT SYSTEM$266
- AcrySof IQ VIVITY IOL$242
- Hydrus Microstent$149
- ARTEVO 800$134
- RXSIGHT CONTACT LENS$131
- RXSIGHT INJECTOR CARTRIDGE$131
- RXSIGHT INJECTOR HANDPIECE$131
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$131
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$131
- ACTHAR$131
- RESTASIS$125
- TRYPTYR$125
- DEXTENZA$125
How this compares
$27,048 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 53 | $42,345 |
| RhopressaNetarsudil Mesylate | 62 | $35,133 |
| LumiganBimatoprost | 56 | $34,466 |
| VyzultaLatanoprostene Bunod | 57 | $32,956 |
| MieboPerfluorohexyloctane/Pf | 29 | $31,977 |
| RestasisCyclosporine | 15 | $26,128 |
| CombiganBrimonidine Tartrate/Timolol | 56 | $19,605 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 62 | $17,500 |
| Cyclosporine | 26 | $16,014 |
| XiidraLifitegrast | 13 | $11,480 |
| Prednisolone Acetate | 309 | $9,741 |
| Brimonidine Tartrate | 218 | $9,399 |
| Alphagan PBrimonidine Tartrate | 21 | $9,337 |
| Bromfenac Sodium | 59 | $7,989 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 534 | $7,514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $20,819 | $89,537148 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $404 | $77,478115 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Miebo, Xiidra | $218 | $76,41399 claims |
| AlconSimbrinza | $1,422 | $17,50062 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $52 | $6,69138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in New York
- Douglas JabsNew York$24.3M
- Nathan RadcliffeNew York$2.4M
- Richard SpaideNew York$1.7M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
- Sharon KehNew York$941K
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$704K
- Joshua KimNew York$677K
- Eric RosenbergNew York$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.